These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33008327)

  • 1. Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
    Wang B; Li D; Liu T; Wang H; Luo F; Liu Y
    BMC Infect Dis; 2020 Oct; 20(1):723. PubMed ID: 33008327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
    Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
    Liu J; Du C; Pu L; Xiang P; Xiong H; Xie W; Chen Z; Li A
    BMC Infect Dis; 2021 Aug; 21(1):885. PubMed ID: 34461841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
    Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
    J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment.
    Ford N; Vitoria M; Rangaraj A; Norris SL; Calmy A; Doherty M
    J Int AIDS Soc; 2020 Apr; 23(4):e25489. PubMed ID: 32293807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
    Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.
    Liu JY; Hua MX; Du CJ; Pu L; Xiang P; Li CS; Xiong HF; Liu XZ; Chen ZH; Xie W; Li A
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11939-11944. PubMed ID: 33275267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
    Wang N; Zhan Y; Zhu L; Hou Z; Liu F; Song P; Qiu F; Wang X; Zou X; Wan D; Qian X; Wang S; Guo Y; Yu H; Cui M; Tong G; Xu Y; Zheng Z; Lu Y; Hong P
    Cell Host Microbe; 2020 Sep; 28(3):455-464.e2. PubMed ID: 32707096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.
    Ye XT; Luo YL; Xia SC; Sun QF; Ding JG; Zhou Y; Chen W; Wang XF; Zhang WW; Du WJ; Ruan ZW; Hong L
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3390-3396. PubMed ID: 32271456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
    Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
    J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
    Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
    Bhattacharyya A; Kumar S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bansal S; Avti P; Hazarika M; Sharma S; Mahendru D; Prakash A; Medhi B
    Indian J Pharmacol; 2020; 52(4):313-323. PubMed ID: 33078733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
    Brandariz-Nuñez D; Correas-Sanahuja M; Guarc E; Picón R; García B; Gil R
    Med Clin (Barc); 2020 Oct; 155(7):281-287. PubMed ID: 32718719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
    Dastan F; Nadji SA; Saffaei A; Marjani M; Moniri A; Jamaati H; Hashemian SM; Baghaei P; Abedini A; Varahram M; Yousefian S; Tabarsi P
    Int Immunopharmacol; 2020 Aug; 85():106688. PubMed ID: 32544867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
    Qu J; Li GH; Wang JJ; He GF; Huang JJ; Chen Y; Qu Q; Chen XY; Lu Q
    Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):203-210. PubMed ID: 33090501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First patient management of COVID-19 in Changsha, China: a case report.
    Zhou J; Cao Z; Wang W; Huang K; Zheng F; Xie Y; Jiang D; Zhou Z
    BMC Infect Dis; 2020 Nov; 20(1):824. PubMed ID: 33176693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.